James C Yang
National Cancer Institute (NCI) · NCI - Surgery Branch
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James C Yang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:08 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03745326 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsNational Cancer Institute (NCI) · terminated · Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer · principal investigator
- Ph1/Ph2NCT03190941 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsNational Cancer Institute (NCI) · recruiting · Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer · principal investigator
- Ph1/Ph2NCT02830724 · Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNational Cancer Institute (NCI) · recruiting · Pancreatic Cancer, Renal Cell Cancer, Breast Cancer · principal investigator
- Ph1/Ph2NCT02390739 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerNational Cancer Institute (NCI) · withdrawn · Metastatic Thyroid Cancer · principal investigator
- Ph2NCT02133196 · T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerNational Cancer Institute (NCI) · recruiting · Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC · principal investigator
- Ph1NCT00923390 · Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 ReceptorNational Cancer Institute (NCI) · terminated · Renal Cancer, Kidney Cancer · principal investigator
- Ph1NCT00304460 · Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerNational Cancer Institute (NCI) · completed · Metastatic Melanoma, Renal Cell Cancer · principal investigator
- Ph3NCT00018941 · Interleukin-2 in Treating Patients With Metastatic Kidney CancerNational Cancer Institute (NCI) · completed · Kidney Cancer · study chair
- Ph2NCT00057889 · Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell CancerNational Institutes of Health Clinical Center (CC) · completed · Kidney Cancer · study chair
- Ph1/Ph2NCT00019214 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Generation of T-cell receptors recognizing antigens on non-melanoma tumorsZIABC011337 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2010 to 2025 · $299,849 awarded in 2025Same name and institution; not confirmed by an ID
- Identification and use of T-cell receptors recognizing common tumor mutationsZIABC011843 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2025 · $899,545 awarded in 2025Same name and institution; not confirmed by an ID
- Laboratory and Clinical studies on T-cells recognizing Non-Small Cell Lung CancerZIABC011651 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2025 · $599,696 awarded in 2025Same name and institution; not confirmed by an ID
- Studying Immune Recognition of Epithelial Cancers Using OrganoidsZIABC012153 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 to 2025 · $1,199,392 awarded in 2025Same name and institution; not confirmed by an ID
- Characterizing a novel tumor recognition mechanismZIABC010803 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2013 · $129,321 awarded in 2013Same name and institution; not confirmed by an ID
- Identification of Molecular Factors Associated with Response to Interleukin-2ZIABC011225 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2012 · $138,829 awarded in 2012Same name and institution; not confirmed by an ID
- Tumor-Reactive Immune Cells Generated from Drosphila Antigen Presenting CellsZIABC011228 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2011 · $125,648 awarded in 2011Same name and institution; not confirmed by an ID
- Characterizing a novel tumor recognition mechanismZ01BC010803 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2007 to 2008 · $594,220 awarded in 2008Same name and institution; not confirmed by an ID
- Defining the T-cell Response to Human Renal CancerZ01SC006660 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $594,220 awarded in 2008Same name and institution; not confirmed by an ID
- Generation of T-cell Responses by Dendritic Cell PresentZ01BC010555 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2003 to 2006Same name and institution; not confirmed by an ID
- Clinical and laboratory studies on angiogenesis in RenalZ01SC010295 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2001Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:08 UTC. The ranking covers the 200 most relevant of 278 PubMed records, and a shared surname and initials can bring in a namesake. All 278 on PubMed
- Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol · 20132,733 citationsRCR 77.3
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.N Engl J Med · 20032,184 citationsRCR 45.6
- Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science · 20022,180 citationsRCR 37.3
- 2,095 citationsRCR 39.8
- AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N Engl J Med · 20151,776 citationsRCR 54.0
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res · 20111,739 citationsRCR 38.1
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med · 19981,503 citationsRCR 30.0
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med · 20141,435 citationsRCR 51.2
- 1,313 citationsRCR 39.5
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.J Clin Oncol · 20051,284 citationsRCR 23.9